CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the election of biopharmaceutical veteran Michael W. Bonney to its board of directors.
From 2003 through its acquisition by Merck in 2014, Mr. Bonney was the chief executive officer of Cubist Pharmaceuticals. Mr. Bonney is currently the chief executive officer and chair of Kaleido Biosciences, a biotechnology company focused on the development of novel chemistries to unlock the power of the human microbiome. He also serves as chair of the boards of Alnylam Pharmaceuticals, Inc. and Magenta Therapeutics, is a member of the board for Celgene Corporation and a former partner at Third Rock Ventures. Additionally, Mr. Bonney is a trustee of the four healthcare dedicated closed end mutual funds managed by Tekla Capital Management.
“Sarepta and its board of directors are greatly enhanced with the appointment to our board of Mike Bonney, one of the most respected biopharmaceutical leaders,” said M. Kathleen Behrens, Ph.D., chair of Sarepta’s board of directors. “Mike’s list of accomplishments is long and his impact on this industry has been profound. We will leverage Mike’s experience as we execute our mission to improve the lives of those suffering from rare diseases.”
“Sarepta stands at a moment of great inflection as we continue the successful launch of our first therapy for the treatment of Duchenne muscular dystrophy while accelerating with a sense of urgency our rich precision genetic medicine pipeline,” said Douglas Ingram, Sarepta’s president and chief executive officer. “I am fortunate to have access to the insight and guidance of someone of Mike’s impeccable credentials and nearly unique experience across all aspects of the biopharmaceutical ecosystem as we execute our ambitious plan and fulfil our important commitments to our patients.”
“Sarepta’s mission and technology are critically important for children with DMD, their families and potentially a range of patients living with other diseases,” said Mr. Bonney. “I am delighted to apply my experience to help the company realize its goal to make an important impact for these underserved patient populations.”
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.